Vaxcyte (NASDAQ: PCVX) CFO moves 61,850 shares to GRAT LLC via trust move

Rhea-AI Filing Summary

Vaxcyte, Inc. reported an insider share transfer involving its President and CFO, Andrew Guggenhime. On 01/14/2026, 61,850 shares of common stock were moved from his direct holdings to ALG 2025 GRAT HOLDINGS LLC at a reported price of $0 per share. The filing notes that he is the sole member and manager of this LLC, and that the LLC is wholly owned by a grantor retained annuity trust for which he is the sole annuitant and trustee.

After the transaction, Guggenhime directly held 62,459 shares of Vaxcyte common stock and indirectly held 61,850 shares through ALG 2025 GRAT HOLDINGS LLC.

Insider Trade Summary

123,700 shares gifted

Mixed 2 txns

Insider GUGGENHIME ANDREW

Role PRESIDENT AND CFO

Type	Security	Shares	Price	Value
Gift	Common Stock	61,850	$0.00	--
Gift	Common Stock	61,850	$0.00	--

Holdings After Transaction: Common Stock — 62,459 shares (Direct); Common Stock — 61,850 shares (Indirect, See Footnote)

Footnotes (1)

1. The reported transaction involves the Reporting Person's transfer of shares to ALG 2025 GRAT HOLDINGS LLC, of which Reporting Person is the sole member and manager. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the sole annuitant and trustee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GUGGENHIME ANDREW

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		G	V	61,850(1)	D	$0	62,459	D
Common Stock	01/14/2026		G	V	61,850	A	$0	61,850	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involves the Reporting Person's transfer of shares to ALG 2025 GRAT HOLDINGS LLC, of which Reporting Person is the sole member and manager.

2. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the sole annuitant and trustee.

Remarks:

	Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Vaxcyte (PCVX) disclose in this Form 4?

Vaxcyte disclosed that President and CFO Andrew Guggenhime transferred 61,850 shares of common stock on 01/14/2026 to ALG 2025 GRAT HOLDINGS LLC at a reported price of $0 per share.

Who is the insider involved in the latest Vaxcyte (PCVX) Form 4 filing?

The insider is Andrew Guggenhime, who serves as President and CFO of Vaxcyte, Inc.

How many Vaxcyte (PCVX) shares does the CFO hold after the reported transaction?

Following the transaction, Andrew Guggenhime directly owned 62,459 Vaxcyte common shares and indirectly owned 61,850 shares through ALG 2025 GRAT HOLDINGS LLC.

What entity received the 61,850 Vaxcyte (PCVX) shares from the CFO?

The 61,850 shares of Vaxcyte common stock were transferred to ALG 2025 GRAT HOLDINGS LLC, an entity of which Andrew Guggenhime is the sole member and manager.

How are the indirectly held Vaxcyte (PCVX) shares structured for the CFO?

The indirectly held shares are in ALG 2025 GRAT HOLDINGS LLC, whose entire interest is owned by a grantor retained annuity trust where Andrew Guggenhime is the sole annuitant and trustee.

Does this Vaxcyte (PCVX) Form 4 involve derivative securities?

No. The Form 4 only reports transactions in non-derivative Vaxcyte common stock, with no derivative securities listed in Table II.